Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational Phase IIb Study to Investigate the Efficacy and Safety of Subcutaneous Immunotherapy With a Modified Fish- Parvalbumin Given in Single Rising and Maintenance Doses to Subjects Allergic to Fish

NCT02382718 is registered in ClinicalTrials.gov with George Stavroulakis as lead sponsor.

NCT NCT02382718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02382718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational Phase IIb Study to Investigate the Efficacy and Safety of Subcutaneous Immunotherapy With a Modified Fish- Parvalbumin Given in Single Rising and Maintenance Doses to Subjects Allergic to Fish
Lead sponsor
George Stavroulakis
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
April 30, 2017
Enrollment
45 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

food allergy to fish